2025
$1.55
▼
OE = CFO - deltaWC - SBC - maintenance capex. Revised Oct 2026: capex now includes patent purchases and patents received as noncash license consideration (replenishment of the core wasting asset; noncash patent revenue appears to be removed from CFO through the working-capital lines, so it is charged here as a patent acquisition); whole series recomputed on this basis. CFO=$158,086K; deltaWC (AR +$5,516K, unbilled contracts receivable -$65,214K, other assets -$5,505K, AP -$2,457K, accrued/other -$776K, deferred revenue -$14,377K) = -$82,813K; SBC=$34,674K; capex = PP&E $1,806K + patents purchased $6,950K + noncash patents est. $25,716K (5.8% of $443,386K revenue per 10-K) = $34,472K; capex_ratio 4.767% x revenue growth $67,362K = growth capex $3,211K, maintenance capex=$31,261K. OE=158,086+82,813-34,674-31,261=$174,964K; diluted shares=112,747K; OE/sh=$1.5518. Unreconciled item: CFO line 'deferred income tax and other' was +$33,678K while deferred tax was a $(21,101)K benefit, implying ~$55M of other non-cash add-backs not itemized in the filing; this lifts FY2025 OE. Non-recurring revenue was $92.0M (Disney settlement/license Q4 2025). Source: FY2025 10-K, accession 0001193125-26-076549.
2024
$0.96
▼
OE = CFO - deltaWC - SBC - maintenance capex. Revised Oct 2026: capex now includes patent purchases and patents received as noncash license consideration (replenishment of the core wasting asset); whole series recomputed on this basis. CFO=$212,461K; deltaWC (AR +$6,256K, unbilled contracts receivable -$18,052K, other assets +$7,414K, AP -$372K, accrued/other +$3,684K, deferred revenue +$54,274K) = +$53,204K; SBC=$26,641K; capex = PP&E $1,821K + patents purchased $20,476K + noncash patents est. $2,256K (0.6% of $376,024K revenue per 10-K disclosure) = $24,553K; revenue declined YoY so growth capex=$0, maintenance capex=$24,553K. OE=212,461-53,204-26,641-24,553=$108,063K; diluted shares=113,061K; OE/sh=$0.9558. Source: FY2025 10-K, accession 0001193125-26-076549.
2023
$1.51
▼
OE = CFO - deltaWC - SBC - maintenance capex. Revised Oct 2026: capex now includes patent purchases and patents received as noncash license consideration (replenishment of the core wasting asset); whole series recomputed on this basis. CFO=$152,755K; deltaWC (AR +$18,268K, unbilled contracts receivable -$34,303K, other assets -$4,502K, AP -$894K, accrued/other -$14,604K, deferred revenue -$7,355K) = -$43,390K; SBC=$18,057K; capex = PP&E $3,812K + patents purchased $2,531K + noncash patents est. $778K (0.2% of $388,788K revenue per 10-K disclosure) = $7,121K; revenue declined YoY so growth capex=$0, maintenance capex=$7,121K. OE=152,755+43,390-18,057-7,121=$170,967K; diluted shares=112,849K; OE/sh=$1.5150. Reconciles to filed CFO via NI $67,372K + dep $1,539K + amort $93,735K + SBC $18,057K + deferred tax/other $11,392K + debt cost amort $4,302K + other $(252)K + deltaWC $(43,390)K. Source: FY2025 10-K, accession 0001193125-26-076549.
2022
$1.58
▼
OE = CFO - deltaWC - SBC - maintenance capex. Revised Oct 2026: capex now includes patent purchases (PaymentsToAcquireIntangibleAssets) and patents received as noncash license consideration, because for a patent licensor these replenish the core wasting asset; whole series recomputed on this basis. CFO=$183,023K; deltaWC (AR +$24,892K, unbilled contracts receivable -$86,673K, other assets -$3,243K, AP +$18,601K, accrued/other -$3,614K, deferred revenue -$215K) = -$50,252K; SBC=$52,626K; capex = PP&E $12,576K + patents purchased $290K + noncash patents $0 (not disclosed for 2022) = $12,866K; capex_ratio=mean(capex/revenue FY22-25)=4.767%; revenue +$47,721K so growth capex=$2,275K, maintenance capex=$10,591K. OE=183,023+50,252-52,626-10,591=$170,058K; diluted shares=107,580K; OE/sh=$1.5808. Caveat: FY2022 cash flows include nine months of the Xperi product business spun off Oct 1, 2022 (its operating cash flow was only +$2.3M but SBC and capex include product-business amounts), so this year is excluded from the valuation anchor. Source: FY2022 10-K, accession 0000950170-23-005437 (CFO, deltaWC, SBC, capex) and FY2023 10-K, accession 0000950170-24-019362 (patent purchases).
Owner's earnings per share by fiscal year, most recent first. Tap a row to see how that figure was calculated, including the source filing.